Articles tagged with Positron Emission Tomography
Researchers are developing new imaging tools to identify abnormalities that cause heart attacks, with the potential to save thousands of lives each year. The project aims to create new chemicals to illuminate unstable plaques in patients, enabling doctors to pinpoint people at higher risk of heart attack.
Researchers have developed a new technique using Cerenkov luminescence imaging (CLI) to assess tumor margins during breast tumor surgery. This method combines optical and molecular imaging, providing high-resolution images of the tumor and surrounding tissue.
Researchers found that social laughter leads to increased release of endorphins and opioid peptides, promoting social bonding and feelings of safety. This chemical response may underlie individual differences in sociability, highlighting the importance of vocal communication in maintaining human social networks.
A new Finnish research reveals how brain's opioids modulate responses to others' pain. The less opioid receptors the participants had, the stronger their emotion and pain circuits' response to seeing others in distress.
Researchers at Waseda University developed the world's first compact Compton camera for medical imaging, capturing high-resolution 3D molecular images of a live mouse in just 2 hours. The device weighs only 580g and can image energy from hundreds to mega-electron volts.
Researchers at Duke University and CalTech have developed a hybrid imaging technology that combines light and ultrasound to provide live, holistic views of small animal organs. This technique breaks the resolution and speed barriers in whole-body imaging, enabling functional imaging of entire bodies with sub-millimeter-level resolution.
A noninvasive PET imaging method measuring granzyme B can distinguish responders from nonresponders to immune checkpoint inhibitors. The method accurately predicted treatment outcomes in both mice and human melanoma samples.
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria for ventilation/perfusion imaging in pulmonary embolism. The guidelines aim to promote cost-effective and appropriate utilization of advanced diagnostic imaging services, affecting approximately 300,000 Americans each year.
Researchers developed new engineered PET tracers to image immune checkpoint expression in cancer cells, enabling monitoring of targeted immunotherapy. The study shows practical immunoPET radiotracer design modifications and their effects on human PD-L1 immune checkpoint imaging.
The Society of Nuclear Medicine and Molecular Imaging has published appropriate use criteria (AUC) for bone scintigraphy in patients with prostate or breast cancer. The new AUC aim to improve healthcare outcomes by making the use of bone scintigraphy more consistent and reducing unnecessary imaging costs.
A new collagen-targeting PET probe, Ga-CBP8, has shown promise in diagnosing and staging pulmonary fibrosis, as well as monitoring treatment response. The probe can differentiate between stable disease and progressive fibrosis, allowing for more effective treatment planning.
Researchers used positron emission tomography (PET) to identify genetic cell mutations that cause lung cancer. Advanced image analysis technique, radiomics, non-invasively identified underlying cell mutations in NSCLC patients.
Researchers used cold pressor tests to assess the relationship between pain threshold and tolerance, and the associated hemodynamic response in the cerebral cortex. The study found no gender difference in hemodynamic responses to pain but sheds light on hidden differences in biological variables in the human brain.
Researchers at Technical University of Munich found a significant proportion of human bodies contain brown fat, which burns energy at an extraordinary rate. This discovery may lead to more effective obesity and diabetes medications that target brown adipose tissue.
Researchers develop a new PET radiotracer that can quickly identify life-threatening atherosclerotic plaques by detecting inflammation. This breakthrough has the potential to prevent heart attacks and strokes by allowing for early treatment of atherosclerosis.
Researchers have developed a direct radiolabeling method for nanomaterials using nanographene, eliminating the need for chelators. This approach significantly improves bioimaging accuracy and reduces biases. The method was tested in mice models and showed promising results.
Researchers developed a new PET imaging technique that can detect changes in olfactory neuron populations, which are sensitive to neurodevelopmental and neurodegenerative diseases. The technique uses GV1-57 radiotracer to quantify neuron generation and degeneration, providing insights into disease progression.
The EXPLORER consortium has successfully assembled a team of industry partners to build the world's first total-body PET scanner. The scanner promises improved image quality and reduced radiation exposure compared to existing technology, with the potential to transform clinical diagnostics and treatment.
Researchers found that a high-fat, low-sugar diet for 72 hours prior to diagnostic imaging improved the accuracy of diagnosing cardiac sarcoidosis. This technique minimizes indeterminate findings and allows clinicians to better monitor patient progress under treatment.
A novel imaging agent, Zr-89-Df-IAB2M, has been shown to detect metastasis of prostate cancer in both bone and soft tissue lesions with high accuracy. The agent targets PSMA on the exterior of prostate cancer cells, allowing for faster and more accurate detection than conventional methods.
Researchers develop a novel method to track an antibody targeting the hormone receptor pathway involved in prostate cancer. The technique uses PET scans to detect and monitor disease progression in real-time, enabling personalized treatment guidance.
Researchers at Johns Hopkins Medicine found evidence of brain injury and repair in young NFL players compared to a control group. PET imaging revealed higher levels of a biomarker associated with brain injury in eight of the 12 brain regions studied, suggesting a link between concussions and chronic traumatic encephalopathy (CTE).
Researchers found higher distribution volume in 8 brain regions among NFL players compared to nonplayers, suggesting localized brain injury may be associated with football play. Limited white matter changes were observed in the brains of NFL players.
A novel mapping technique combines imaging and electroanatomical mapping to guide gene therapy injections into viable myocardium with reduced contractile ability, increasing blood flow in patients with refractory angina. This approach shows promise for repairing damaged heart muscle.
A new study found that cardiac PET/CT imaging can detect calcium in arteries, a sign of plaque buildup, reducing the risk of future heart attack and stroke. Researchers discovered that patients with high levels of calcification were more likely to experience adverse cardiac events.
Researchers have successfully used PET imaging to visualize cardiac amyloidosis, a condition characterized by abnormal protein deposits in the heart. The study showed that F-18-florbetaben PET imaging can accurately identify and differentiate between cardiac amyloidosis and hypertensive heart disease.
Researchers mapped patterns of prostate cancer recurrence using C-11 choline PET imaging and multiparametric MRI, identifying sites of recurrence that can be targeted for radiation therapy. Nearly two-thirds of men had recurrence limited to the pelvis, a potentially treatable area.
A new imaging technique using tau PET has been confirmed to accurately depict changes in the brain associated with Alzheimer's disease. The method reveals tau protein accumulation, which is linked to cell death and can be targeted by new drugs.
The PACIFIC trial compared the accuracy of non-invasive imaging modalities, finding that positron emission tomography (PET) was significantly more accurate than single photon emission computed tomography (SPECT) or coronary computed tomography angiography (CCTA). PET's diagnostic accuracy was 85% for diagnosing coronary ischemia, outpe...
A novel PET radiotracer called Martinostat has been developed to image epigenetic activity in the human brain. The tracer reveals patterns of uptake consistent with histone deacetylase (HDAC) expression levels, providing insights into gene regulation and potential therapies for brain disorders.
A new study published in JAMA Neurology found that tau imaging using [18F]-AV-1451 PET tracing distinguished participants with Alzheimer's from those who were cognitively normal. Elevated binding was also associated with volume loss in parts of the brain.
Researchers developed an automated system to produce fluorine-18 hypoxia radiotracers, overcoming cost and logistical barriers to PET imaging. The system enables consistent, low-cost production of radiotracers, improving patient access to life-saving diagnostic and therapeutic treatments.
A study of 28,000 patients found that increased imaging after initial treatment for thyroid cancer did not lead to better survival rates, but rather more aggressive treatment for recurrence. The researchers emphasize the importance of curbing unnecessary imaging and tailoring care to individual patient risk.
SNMMI recognized Peter Herscovitch and Satoshi Minoshima for their contributions to the field of nuclear medicine through various awards. Dominique Delbeke received the Presidential Distinguished Educator Award for her work as editor of The Journal of Nuclear Medicine.
A new PET/MRI imaging test has been shown to improve the detection of significant prostate cancer, surpassing current multi-parametric MRI methods. The test's addition of molecular imaging based on F-18-choline positron emission tomography (PET) significantly improves the identification of clinically significant cancers.
Researchers have developed a spinach-like, nanoparticle juice that can help doctors get a better look at the human gastrointestinal tract. The drink, made from chlorophyll-based nanoparticles, has shown promise in improving imaging techniques such as photoacoustic and PET imaging.
Doctors used PET scans to identify patients with advanced Hodgkin lymphoma who could safely stop using the potentially toxic drug bleomycin. This approach resulted in similar survival rates and fewer side effects for those who stopped bleomycin compared to those who continued it.
A novel PET imaging study reveals a significant correlation between increased tau and decreased metabolic activity in the brains of living Alzheimer's patients, indicating clear signs of neurodegeneration. The study measures amyloid plaques, tau tangles, and metabolic activity using three different radiotracers.
A novel CT-based calculation method, SULps, accurately measures lean body mass using computed tomography, leading to more precise PET imaging results. This improvement enables better staging of disease and therapy monitoring in cancer patients.
Researchers used PET and SPECT to tailor radionuclide treatment for neuroendocrine cancer patients, reducing the risk of toxicity. The study showed that personalized dosimetry led to a significant alteration in radiotherapy doses, with some patients receiving reduced or increased doses.
A recent study using PET/CT imaging found that the brains of recovering alcoholics have adapted to chemical dependency by significantly hindering metabotropic glutamate receptor subtype 5 (mGluR5) receptors, reducing cravings. This discovery could lead to new targeted drugs to limit receptor activity in patients at risk of relapse.
Peter S. Conti, MD, PhD, receives the prestigious Paul C. Aebersold Award for his groundbreaking work in developing novel diagnostic imaging agents for oncology applications. His research focuses on PET imaging and gene expression, advancing the field of nuclear medicine and molecular imaging.
Researchers developed PET tracers that can visualize inflammatory disease and evaluate next-generation MS therapies. The study found that the compounds could detect an increase in S1P1 expression in animals with an inflammatory response, suggesting a promising approach for imaging MS and other inflammatory diseases.
Researchers have developed a new method for detecting and diagnosing preclinical Alzheimer's disease using PET imaging with PiB, which binds to amyloid plaques in the brain. The study found that PiB retention was prominent in cortical areas of the brain, consistent with post-mortem studies of Aβ plaques.
Researchers found that tau tangles are a better indicator of dementia in late-stage Alzheimer's disease, correlating with cognitive deficits and cerebrospinal fluid tau levels. PET imaging also showed stronger associations between tau deposits and amyloid plaques than previously thought.
Researchers at WashU Medicine have developed a new imaging agent that better predicts Alzheimer's disease progression than amyloid beta. The study found elevated tau levels are associated with cognitive decline and predict symptoms of dementia.
Researchers at the University of Bergen have identified PET scanning as an effective tool for improved oil production and CO2 storage. The technology uses radioactive tracers to visualize the flow of liquid or gas in rock samples, increasing the efficiency of CO2 storage and oil production.
A clinical trial found that using PET imaging to guide chemotherapy significantly increases remission rates and reduces toxic side effects in advanced Hodgkin lymphoma patients. The study showed a promising approach to tailor treatment to individual patients, leading to a potential new standard of care.
Researchers found that combining computed bioconductance (CB) with positron emission tomography (PET) before biopsy can improve the detection of potentially cancerous lung lesions. This non-invasive diagnostic tool may aid in the accurate evaluation of suspicious lung lesions.
A recent study published in Neurology found that maintaining mental activity can slow the onset of Alzheimer's symptoms in people without a family history of the disease. For those with the APOE4 gene, continued learning and intellectual activity in middle age can lower amyloid plaque levels.
A national look at PET scan use for lung and esophageal cancer survivors found widespread variation between hospitals, with some using scans eight times more often than others. The study suggests that this approach doesn't improve survival rates and is being inappropriately used at many hospitals.
A study published in the JNCI: Journal of the National Cancer Institute found that PET scans did not improve two-year survival rates for lung and esophageal cancer patients. The researchers suggest potential overuse of PET scans in detecting recurrence, warranting efforts to decrease unnecessary utilization.
Researchers at Uppsala University have developed a new PET imaging method that uses monoclonal antibodies to provide more precise information on the brain than traditional radioactive tracers. The method has shown high specificity and can monitor the progression of Alzheimer's disease, allowing for better assessment of medication effects.
A recent study shows that a PET/CT scan using F-18-DCFBC is significantly more effective in detecting metastatic prostate cancer than other detection methods. The radiotracer targets prostate-specific membrane antigen, which is expressed in the majority of prostate cancers and associated with metastatic spread.
The new risk management plan aims to prioritize data quality, reduce costs, and decrease attrition rates in imaging biomarker-driven trials. By identifying risks at trial initiation and allocating resources effectively, the framework can help minimize variability and ensure reproducibility of data.
Researchers have successfully implemented time-of-flight PET scanning technology, reducing the radiation dose for cancer patients and staff by up to 30%. This has allowed an additional 100 scans per year at Central Manchester University Hospitals.
The Berkeley Lab team is developing electronics that will send data from the scanner's detectors to a computer, converting it into a three-dimensional image of the patient. This new scanner will have half a million detectors, reducing a patient's radiation dose by a factor of 40 and scanning time from 20 minutes to just 30 seconds.
A UC Davis research team has been awarded $15.5 million to develop the world's first total-body PET scanner, which could revolutionize cancer tracking and treatment. The new technology allows for simultaneous imaging of the entire body, reducing radiation dose by a factor of 40 and scanning time from 20 minutes to just 30 seconds.
A new Lund University study found that both amyloid PET imaging and cerebrospinal fluid samples are effective methods for detecting early-stage Alzheimer's disease. The two methods identified approximately 90% of patients with the disease, making them equally viable options.
A novel radiopharmaceutical probe has been developed to detect blood clots anywhere in the body using whole-body PET scans. The probe can distinguish recently formed clots from older ones and reveal clot composition, which can determine treatment response.